|
GC Biopharma Corp. is a pharmaceutical and biotechnology company that manufactures and sells blood products, vaccines, prescription drugs, and over-the-counter medications. Its core business segments include blood products, such as immunoglobulins and albumin, and vaccines, including influenza and varicella formulations. Key products include ALYGLO, an intravenous immunoglobulin approved by the FDA in 2023 and launched in the United States in 2024, and Barycela, a second-generation varicella vaccine that received WHO prequalification in 2023. The company also develops gene-recombinant therapies for rare diseases, notably Hunterase for Hunter syndrome and GreenGene F for hemophilia, with GreenGene F approved in China in 2021. GC Biopharma serves hospitals, clinics, pharmacies, and wholesalers in South Korea and international markets, including the United States, China, and countries in Latin America and Southeast Asia. The company operates subsidiaries such as GC Biopharma USA for North American sales and GC DO BRASIL for South American market expansion. It maintains a research and development focus on next-generation vaccines, including a shingles vaccine in clinical trials, and rare disease therapeutics. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage gcbiopharma.com |
| Sector Healthcare | IR page gcbiopharma.com/kor/index.do | |
|
Tags
blood products, vaccines, rare disease therapeutics, hemophilia, hunter syndrome, influenza vaccines, varicella vaccines, immunoglobulins, gene-recombinant drugs, otc medications, ALYGLO, Barycela, Hunterase, GreenGene F, GC Biopharma USA, GC DO BRASIL, Curevo Inc., GC Biopharma Corp., GC Biopharma, IVIG-SN, Hepabig, EUGAMMA, GCFLU, GC1123B, GC1130A, GC1134A, GC4006A, GC3111B, MG1111D, GC3107A, GCC5694A, Nokxaban, Glazia, Livmarli, Lynex, Dr.PNT, Youthfill, Fillode, DuraGen, LaraShot Q, NovaStem BC Kit, Inibo, GC Wellness, GC Biopharma USA Inc., GC DO BRASIL CONSULTORIA DE NEGÓCIOS LTDA
|
Press page gcbiopharma.com/kor |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 1.418T |
| Market cap (USD) | $ 1.044B |
| P/E | -27.75 |
| PEG | — |
| P/BV | 1.15 |
| P/S | 0.72 |
| P/OCF | 7.70 |
| P/FCF | 16.16 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -0.38% |
| ROI | -0.38% |
| ROIC | 4.3% |
| Profit margin | -0.23% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.991T | 1.68T | 1.627T | 1.711T | 1.538T | 1.504T | 1.37T | 1.335T | 1.288T | 1.198T | 1.048T | 975.327B | 888.168B |
| Net profit | -4.674B | -26.28B | -26.632B | 65.453B | 123.212B | 81.049B | -3.638B | 34.429B | 53.247B | 62.97B | 94.967B | 83.945B | 70.066B |
| Free cash flow | 27.101B | -85.452B | -84.56B | 61.158B | 23.658B | -46.902B | -87.163B | -26.976B | 28.386B | -82.411B | -75.908B | -1.712B | -53.894B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 345B | 368B | 391B | 405B | 424B | 425B | 414B | 453B | 387B | 403B |
| ↳ YoY growth | +19.6% | +6.7% | +6.3% | +3.6% | +4.6% | +0.2% | -2.6% | +9.5% | -14.7% | +4.2% |
| ↳ 5y CAGR | +8.9% | +10.4% | +8.0% | +4.2% | +2.4% | +3.0% | -0.9% | -1.0% | ||
| Other receivables (KRW) | — | — | — | — | — | — | 19.8B | 16.3B | 21.4B | 6.85B |
| Borrowings, current (KRW) | 13.8B | — | — | — | — | — | 187B | 518B | 378B | 609B |
| Borrowings, non-current (KRW) | — | — | — | — | — | — | 279B | 84.9B | 340B | 254B |
| Lease liabilities (KRW) | — | — | — | 76.8B | 77.9B | 101B | 109B | 121B | 111B | 120B |
| Cash and deposits (KRW) | 56.9B | 171B | 96.6B | 98.5B | 232B | 186B | 105B | 49.7B | 22.6B | 49.4B |
| Intangible assets (KRW) | 73.6B | 87.9B | 101B | 103B | 110B | 277B | 312B | 338B | 307B | 337B |
| Right-of-use assets (KRW) | — | — | — | 77.1B | 77.4B | 101B | 108B | 125B | 111B | 116B |
| Net debt (borrowings + leases - cash) (KRW) | -43.2B | — | — | — | — | — | 470B | 589B | 806B | 933B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | -1.74B | 57.9B | 14.4B | 40.3B | 36B | 126B | 119B | -5.47B | -53.5B | 99.5B |
| Purchases of property, plant and equipment (KRW) | -80.7B | -29.5B | -41.4B | -127B | -82.9B | -102B | -58B | -79.1B | -32B | -72.4B |
| Purchases of intangible assets (KRW) | -18B | -26.1B | -23.6B | -20.2B | -18.5B | -21.2B | -36.7B | -46.9B | -10.4B | -32.9B |
| Dividends paid (cash effect) (KRW) | -20.5B | -15.3B | -15.3B | -12.4B | -12.7B | -18.5B | -24B | -24.8B | -19.5B | -18.8B |
| Share buybacks (cash effect) (KRW) | -21.8B | -538M | — | — | — | — | — | — | — | — |
| Interest paid (cash effect) (KRW) | -4.59B | -5.83B | -6.55B | -7.06B | -9.73B | -13.5B | -19.4B | -24.1B | -38.1B | -38.3B |
| Income taxes paid (cash effect) (KRW) | -43.3B | -15B | -15.4B | -17.8B | -8.98B | -18.9B | -37.3B | -19B | -2.47B | -11.1B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -100B | 2.31B | -50.6B | -107B | -65.4B | 2.44B | 24.5B | -131B | -95.9B | -5.82B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 66.8B | 65.4B | 29.8B | -14.8B | 88.1B | 139B | 83.6B | -3.26B | -50.5B | -42.9B |
| Comprehensive income to owners (KRW) | 65.1B | 61.6B | 30.8B | -5.6B | 80.1B | 125B | 74.7B | -7.99B | -33.2B | -18.1B |
| Reported | Mar 31, 2017 | Jun 18, 2018 | Apr 1, 2019 | Mar 30, 2020 | Apr 28, 2021 | Mar 20, 2024 | Mar 18, 2025 | Mar 18, 2025 | Mar 18, 2025 | Mar 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding GC Biopharma Corp.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.06% | 737 | $ 72.512K | Nov 16, 2026 |
| AVES | 0.03% | 4,293 | $ 422.38K | Nov 16, 2026 |
| DFEV | 0.01% | 2,853 | $ 300.214K | Nov 12, 2026 |
| AVEM | 0.01% | 26,353 | $ 2.593M | Nov 16, 2026 |
| DFSE | 0.01% | 541 | $ 56.928K | Nov 12, 2026 |
| DFEM | 0.01% | 7,177 | $ 755.218K | Nov 12, 2026 |
| DFAE | 0.01% | 5,347 | $ 562.652K | Nov 12, 2026 |
| DFAX | 0.00% | 4,813 | $ 506.46K | Nov 12, 2026 |
| DEXC | 0.00% | 77 | $ 8,102.52 | Nov 12, 2026 |
| AVXC | 0.00% | 101 | $ 9,937.19 | Nov 16, 2026 |






